Abstract

Men with metastatic castration-resistant prostate cancer (CRPC) typically survive about 1 to 2 years after progression on hormonal therapy. Until 2010,

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call